RxDoctor Payments Data

Holly Barden

Nurse Practitioner · Monroe, NCNPI 1043728660

Payments from drug & device makers

$1,880in general payments, 2019–2025

Across 79 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$341
  • Amgen$294
  • Boehringer Ingelheim$215
  • Scpharmaceuticals Inc.$202
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$187
  • Novartis$170
  • plus $471 from 9 others

What the payments were for

  • Food & beverage$1,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,880 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,858
Medicare patients
340
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$98,251
EntrestoSacubitril/Valsartan32$33,030
Repatha SureclickEvolocumab15$18,287
XareltoRivaroxaban21$15,630
Metoprolol Succinate195$2,112
Ranolazine ErRanolazine20$2,016
Flecainide Acetate52$1,473
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$1,169
Midodrine Hcl20$1,058
Atorvastatin Calcium85$993
Ezetimibe36$868
Amlodipine Besylate145$805
Lisinopril82$717
Isosorbide Mononitrate ErIsosorbide Mononitrate53$687
ClopidogrelClopidogrel Bisulfate43$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$98,251109 claims
NovartisEntresto$170$33,03032 claims
Johnson & JohnsonXarelto$341$15,63021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Monroe

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →